Express Scripts reports net income of $391.4 million for third quarter 2012

Express Scripts (Nasdaq: ESRX) announced 2012 third quarter net income of $391.4 million, or $0.47 per diluted share.  Adjusted earnings per share, as detailed in Table 4 were $1.02 per diluted share for the third quarter.

"Our solid third quarter results demonstrate our continued success as a combined organization," stated George Paz, chairman and chief executive officer.  "Integration continues on track and together we are building on our legacy of advancing healthcare through innovation and an unwavering alignment with our clients."

Third Quarter 2012 Review (Data reflected on an adjusted basis. See Tables 2 and 3)

All key metrics compared to 2011 were affected by the inclusion of Medco results beginning in the second quarter of 2012.  Gross profit margin and EBITDA per adjusted claim increases over last year are mainly attributed to improved operating performance, including increased generic utilization.

• Adjusted claims of 398.9 million, up 116% from third quarter 2011  
• Gross profit of $2.2 billion, up 153% from third quarter 2011
• Gross profit margin of 8.1% up from 7.5% in third quarter 2011
• EBITDA of $1.6 billion, up 136% from third quarter 2011
• EBITDA per adjusted claim of $4.06, up 9% from third quarter 2011
• Year to date cash flow from operations of $2.0 billion, up 23% from third quarter 2011

2012 Guidance

Due to strong operating performance, increased generic utilization and the accelerated realization of synergies, the Company now expects to achieve adjusted earnings per share for 2012 in the range of $3.65 to $3.75.  Adjusted earnings per share excludes items as detailed in Table 5. 

Total adjusted claims are expected to be approximately 1.4 billion.  The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range.

The successful integration of Medco continues, with the Company meeting or exceeding its targets.

2013 Economic and Environmental Outlook

Express Scripts previously announced that it will provide 2013 guidance in conjunction with its fourth quarter results.  In addition to the expected claims loss from the UnitedHealthcare book of business throughout the year, the Company believes its 2013 outlook will also be influenced by the current weak business climate and the unemployment outlook.  These factors would likely result in significant in-group member attrition, continued low utilization rates and increased client demands and expectations.

Express Scripts expects to grow earnings per share and EBITDA in 2013.  However, given the factors discussed above, the Company views current consensus estimates for 2013 as overly aggressive.

"Despite near-term headwinds and a challenging macroeconomic environment, we remain confident we are well-positioned for continued growth", stated Paz.  "We have historically managed expenses rigorously while investing toward the future, focusing on innovation, service and optimal clinical outcomes, and will continue to do so, even when faced with challenges on other fronts."